Last reviewed · How we verify
Second-line systemic treatment
Second-line systemic treatment refers to a category of therapeutic interventions administered after first-line therapy has failed or become unsuitable, rather than a single drug with a defined mechanism.
Instituto de Investigación Hospital Universitario La Paz is exploring second-line systemic treatments across various cancers, including SCLC, biliary tract cancer, and advanced gastric cancer. Key trials are evaluating combinations with radiation therapy and immunotherapy, aiming to improve efficacy and patient outcomes.
At a glance
| Generic name | Second-line systemic treatment |
|---|---|
| Also known as | Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib |
| Sponsor | Instituto de Investigación Hospital Universitario La Paz |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is a clinical classification describing the treatment sequence in a disease management algorithm, not a specific pharmaceutical agent. Second-line systemic treatments vary widely depending on the disease context (oncology, rheumatology, infectious disease, etc.) and may include chemotherapy, targeted therapy, immunotherapy, or other systemic agents. The specific mechanism depends entirely on which drug is selected as second-line therapy.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: